Oct 28HHS draft policy lets licensed pharmacies compound six peptides, including BPC-157. What changed and what did not.
Skip to content
PeptideAgent

Are peptides legal? Peptide laws in all 50 states

It depends on the peptide, not only the state. FDA approved peptide drugs are legal in all 50 states with a prescription. Most other peptides sold online are unapproved drugs: selling them for human use violates federal law, and a pharmacy can compound one only when federal 503A rules allow it.

Federal law decides which peptides can be approved or compounded at all. Your state decides who may prescribe them by telehealth, which pharmacies may ship to you, and how its pharmacy board treats compounding. Pick your state below for its statute, board, and sources.

By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed.  Last verified

The federal framework for peptides

Five federal rules decide whether a peptide can lawfully reach a patient. States can be stricter than this floor but not looser.

  • FDA approval. An approved peptide drug can be prescribed and dispensed anywhere in the country with a prescription. [25]
  • 503A compounding, the bulks list, and Category 2. A state-licensed pharmacy may compound for an individual prescription only from a substance that is part of an approved drug, has a USP or NF monograph, or is on the FDA 503A bulks list. Substances FDA places in Category 2 raised significant safety concerns and are not eligible. [1] [2] [4] [5]
  • The Pharmacy Compounding Advisory Committee (PCAC). FDA’s advisory committee reviews nominated substances before FDA decides by rule whether to list them. At its July 2026 meeting, for BPC-157, KPV, TB-500, MOTS-c, semax, and epitalon, FDA’s drug center recommended against listing and the committee voted in favor, according to Appendix B of HHS’s October 2026 draft policy. FDA has proposed no rule, so none of the six is on the 503A bulks list. [1] [7] [17]
  • 503B outsourcing facilities. FDA-registered outsourcing facilities can compound without patient-specific prescriptions, but under their own bulks list and current good manufacturing practice. [6]
  • “Research use only” sales. A peptide marketed or sold for human use without approval is an unapproved new drug, whatever its label says, and FDA has sent warning letters to online sellers. [11] [12] [13]

Update, October 28, 2026. HHS released a draft enforcement discretion policy for six peptides: BPC-157, epitalon, KPV, MOTS-c, semax, and TB-500. HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician that compounds one of them as a single-ingredient product, by an allowed route, on a patient-specific prescription, with tested bulk substance from an FDA-registered manufacturer. It is a draft, not an FDA approval or a bulks list entry, and it does not cover blends or other peptides. the notice was published in the Federal Register on October 30, 2026. [16] [17] What the HHS draft peptide policy covers.

Sport is a separate question. The WADA Prohibited List bans unapproved substances and peptide hormones in tested competition whether or not a peptide is legal to prescribe. [26]

Federal summary

Federal law sets the floor for every state: an FDA approved peptide (semaglutide, tirzepatide, tesamorelin, bremelanotide) can be prescribed and dispensed anywhere in the country, and a compounded peptide can only be made by a licensed pharmacy from a substance that is an approved drug component, has a USP or NF monograph, or appears on the FDA 503A bulk drug substances list. Peptides that FDA has placed in 503A Category 2 or 3, or whose nominations were withdrawn, are not eligible for pharmacy compounding, and "research use only" peptides sold for human use are unapproved drugs under the Federal Food, Drug, and Cosmetic Act. A draft HHS enforcement discretion policy released October 28, 2026 says HHS will not act against 503A compounding of six withdrawn peptides (BPC-157, epitalon, KPV, MOTS-c, semax, TB-500) that meets strict conditions, but it is not an FDA approval or a bulks listing. States can be stricter than this floor but not looser.

Federal rules for peptides and compounding

What you’ll actually find, and how to check

Licensed compounding pharmacies, clinics, and telehealth prescribers openly offer many unapproved peptides, and prescribers write prescriptions for them. [27] [28] [29]

  • No FDA oversight of the specific product: FDA does not check a compounded drug's safety, effectiveness, or quality before it is sold. [3]
  • State boards can act. On August 19, 2026, Mississippi's medical, nursing, and pharmacy boards said no licensed provider may prescribe, recommend, supply, or administer a peptide that is not FDA approved, and that a consent form does not remove the provider's liability. [30]
  • Louisiana acted by statute: Act 374, in effect August 1, 2026, bars its licensing boards from prohibiting peptides only when they come from a pharmacy or outsourcing facility that complies with federal compounding law. It does not make any peptide eligible to compound. [31] [32]

If you're going ahead anyway

These steps lower some risks. They do not make a compounded product safe, and FDA has not reviewed it. [3] They do not change a peptide's legal status either. That depends on the peptide: for a withdrawn nomination such as BPC-157 or TB-500, a 503A pharmacy has no federal basis to compound it from bulk, with or without a prescription, while a few Category 1 substances, such as NAD+ and glutathione, are compounded under FDA's interim policy, with conditions. Each peptide page gives its status. [4] [33] [34]

The checklist covers:

  • Check the pharmacy's license
  • What a legitimate prescription and consult look like
  • Why this is safer than a research-use-only product
  • Questions to ask the prescriber, pharmacy, and telehealth company

Read the full checklist, or pick your state in the table below for its board’s license search and any action it has taken.

FDA peptides: approvals and compounding status

Every peptide in this database carries one FDA status, taken from FDA and Federal Register sources and dated on its page. The FDA peptide regulatory tracker logs each change, from Category 2 decisions to advisory committee votes and final rules.

  • 35Regulatory: FDA approved
  • 6Regulatory: HHS interim policy (draft)
  • 3Regulatory: In FDA review (Category 1)
  • 11Regulatory: Nomination withdrawn
  • 11Regulatory: Not eligible for compounding
  • 15Regulatory: Unscheduled
  • 1Regulatory: Former FDA approval (Geref)

In FDA’s Category 1, compounded under its interim policy: Glutathione, NAD+, VIP (vasoactive intestinal peptide).

Which peptides are FDA approved?

35 peptides in this database are FDA approved drugs. Approval covers the uses on each label; anything else is off label. [25]

Peptide laws in all 50 states

Of 50 states with a published record, 50 allow telehealth prescribing, 29 allow a prescription without a live visit (asynchronous care), and 50 limit or bar routine compounded GLP-1s. Badges summarize the record; the state page has the statute and caveats.

Telehealth, asynchronous prescribing, and compounded GLP-1 access by state
StateTelehealthAsync prescribingCompounded GLP-1Verified
Alabama ALRegulatory: AllowedRegulatory: AllowedRegulatory: Limited
Alaska AKRegulatory: AllowedRegulatory: UnclearRegulatory: Limited
Arizona AZRegulatory: AllowedRegulatory: AllowedRegulatory: Limited
Arkansas ARRegulatory: AllowedRegulatory: Not allowedRegulatory: Limited
California CARegulatory: AllowedRegulatory: AllowedRegulatory: Limited
Colorado CORegulatory: AllowedRegulatory: AllowedRegulatory: Limited
Connecticut CTRegulatory: AllowedRegulatory: AllowedRegulatory: Limited
Delaware DERegulatory: AllowedRegulatory: AllowedRegulatory: Limited
Florida FLRegulatory: AllowedRegulatory: AllowedRegulatory: Limited
Georgia GARegulatory: AllowedRegulatory: Not allowedRegulatory: Limited
Hawaii HIRegulatory: AllowedRegulatory: AllowedRegulatory: Limited
Idaho IDRegulatory: AllowedRegulatory: AllowedRegulatory: Limited
Illinois ILRegulatory: AllowedRegulatory: UnclearRegulatory: Limited
Indiana INRegulatory: AllowedRegulatory: UnclearRegulatory: Limited
Iowa IARegulatory: AllowedRegulatory: AllowedRegulatory: Limited
Kansas KSRegulatory: AllowedRegulatory: UnclearRegulatory: Limited
Kentucky KYRegulatory: AllowedRegulatory: UnclearRegulatory: Limited
Louisiana LARegulatory: AllowedRegulatory: Not allowedRegulatory: Limited
Maine MERegulatory: AllowedRegulatory: AllowedRegulatory: Limited
Maryland MDRegulatory: AllowedRegulatory: AllowedRegulatory: Limited
Massachusetts MARegulatory: AllowedRegulatory: AllowedRegulatory: Limited
Michigan MIRegulatory: AllowedRegulatory: AllowedRegulatory: Limited
Minnesota MNRegulatory: AllowedRegulatory: UnclearRegulatory: Limited
Mississippi MSRegulatory: AllowedRegulatory: Not allowedRegulatory: Limited
Missouri MORegulatory: AllowedRegulatory: UnclearRegulatory: Limited
Montana MTRegulatory: AllowedRegulatory: AllowedRegulatory: Limited
Nebraska NERegulatory: AllowedRegulatory: AllowedRegulatory: Limited
Nevada NVRegulatory: AllowedRegulatory: AllowedRegulatory: Limited
New Hampshire NHRegulatory: AllowedRegulatory: AllowedRegulatory: Limited
New Jersey NJRegulatory: AllowedRegulatory: AllowedRegulatory: Limited
New Mexico NMRegulatory: AllowedRegulatory: Not allowedRegulatory: Limited
New York NYRegulatory: AllowedRegulatory: UnclearRegulatory: Limited
North Carolina NCRegulatory: AllowedRegulatory: AllowedRegulatory: Limited
North Dakota NDRegulatory: AllowedRegulatory: AllowedRegulatory: Limited
Ohio OHRegulatory: AllowedRegulatory: AllowedRegulatory: Limited
Oklahoma OKRegulatory: AllowedRegulatory: UnclearRegulatory: Limited
Oregon ORRegulatory: AllowedRegulatory: AllowedRegulatory: Limited
Pennsylvania PARegulatory: AllowedRegulatory: UnclearRegulatory: Limited
Rhode Island RIRegulatory: AllowedRegulatory: Not allowedRegulatory: Limited
South Carolina SCRegulatory: AllowedRegulatory: UnclearRegulatory: Limited
South Dakota SDRegulatory: AllowedRegulatory: UnclearRegulatory: Limited
Tennessee TNRegulatory: AllowedRegulatory: AllowedRegulatory: Limited
Texas TXRegulatory: AllowedRegulatory: AllowedRegulatory: Limited
Utah UTRegulatory: AllowedRegulatory: UnclearRegulatory: Limited
Vermont VTRegulatory: AllowedRegulatory: AllowedRegulatory: Limited
Virginia VARegulatory: AllowedRegulatory: AllowedRegulatory: Limited
Washington WARegulatory: AllowedRegulatory: AllowedRegulatory: Limited
West Virginia WVRegulatory: AllowedRegulatory: Not allowedRegulatory: Limited
Wisconsin WIRegulatory: AllowedRegulatory: AllowedRegulatory: Limited
Wyoming WYRegulatory: AllowedRegulatory: UnclearRegulatory: Limited

“Async allowed” means a prescriber may prescribe without a live visit; in 15 of those states the law also says an online questionnaire alone is not enough. “Async unclear” means the state law we checked does not settle it. Rules change; each state page shows the date it was last verified. See also the regulatory tracker and cost index.

For what a prescriber can lawfully write today, and what a legitimate visit includes, read how to get peptides prescribed legally. For what clinics mean by the term, read what peptide therapy is.

Peptide legality FAQ

Are peptides legal?

It depends on the peptide. FDA approved peptide drugs, such as semaglutide, tirzepatide, and tesamorelin, are legal in every state with a prescription. Most other peptides sold online are not approved drugs: selling them for human use violates federal drug law, and a pharmacy can compound one only from a substance that federal 503A rules allow. Of the 82 peptides in this database, 35 are FDA approved. [1] [11] [12] [25]

Are peptides legal in California?

Yes, with limits. A California resident can get FDA approved peptides by prescription from a California-licensed prescriber, including through asynchronous telehealth under Business and Professions Code section 2242. Compounded peptides are harder to get than in most states: the Board of Pharmacy's 2025 compounding rules define an "essentially a copy" product more strictly than federal law, and out-of-state pharmacies shipping sterile injectables need nonresident pharmacy and sterile compounding licenses. Selling unapproved new drugs is barred by Health and Safety Code section 111550. [18] [19] [20] [21]

California peptide laws, statutes, and sources

Are peptides legal in Texas?

Yes, with limits. A Texas resident can get FDA approved peptides from a Texas-licensed prescriber, including by telemedicine under Occupations Code chapter 111, and a compounded peptide when it is eligible under federal 503A rules and dispensed by a pharmacy the Texas State Board of Pharmacy licenses. Out-of-state pharmacies shipping sterile compounded injectables need the Class E-S designation and must meet 22 Texas Administrative Code 291.133. The Texas Food, Drug, and Cosmetic Act bars adulterated or misbranded drugs. [22] [23] [24]

Texas peptide laws, statutes, and sources

Which peptides are FDA approved?

35 peptides in this database are FDA approved drugs, including semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), tesamorelin (Egrifta), and bremelanotide (PT-141, Vyleesi). An approval covers only the uses on the drug's label. The full list is on this page, and Drugs@FDA is the official record. [25]

Is BPC-157 legal?

BPC-157 is not an FDA approved drug and is not on the 503A bulks list. On October 28, 2026, HHS released a draft enforcement discretion policy saying it does not intend to take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician that compounds BPC-157 as a single-ingredient product, by subcutaneous, intramuscular, oral, or topical route, on a patient-specific prescription, from an FDA-registered manufacturer's substance with a tested certificate of analysis. The policy is a draft, is not binding, and does not cover blends such as the Wolverine stack. At the July 2026 advisory committee meeting, FDA's drug center recommended against listing BPC-157 and the committee voted in favor, according to the HHS policy. Research-use-only products sold for human use are still unlawful, and state law still applies. [1] [7] [16] [17]

BPC-157 FDA status tracker

Are peptides banned in sports?

Many are. The WADA Prohibited List bans substances with no current approval for human use at all times (section S0), and it bans growth hormone releasing peptides and other peptide hormones (section S2). A prescription does not change a peptide's status in tested sport, so check each peptide page for its WADA status. [26]

Sources

  1. [1]FDA: Section 503A of the Federal Food, Drug, and Cosmetic ActFDA
  2. [2]21 U.S.C. 353a, Pharmacy compounding (Office of the Law Revision Counsel)
  3. [3]FDA: Compounding and the FDA, questions and answersFDA
  4. [4]FDA: Certain bulk drug substances for use in compounding may present significant safety risks (503A and 503B category lists)FDA
  5. [5]Federal Register: List of bulk drug substances that can be used to compound drug products in accordance with section 503A (final rule, February 19, 2019)Federal Register, 2019
  6. [6]FDA: Information for outsourcing facilities (section 503B)FDA
  7. [7]FDA: Pharmacy Compounding Advisory CommitteeFDA
  8. [8]FDA: concerns with unapproved GLP-1 drugs used for weight loss, including shortage resolution and compounding grace periodsFDA
  9. [9]21 U.S.C. 829, Prescriptions (including subsection (e) on controlled substances dispensed by means of the Internet)
  10. [10]21 CFR 1300.04, Definitions relating to the dispensing of controlled substances by means of the Internet (practice of telemedicine)